Literature DB >> 16014568

Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma.

Erwan Piriou1, Karel van Dort, Nening M Nanlohy, Marinus H J van Oers, Frank Miedema, Debbie van Baarle.   

Abstract

We previously observed a loss of Epstein-Barr virus (EBV)-specific CD8+ T cells in subjects progressing to EBV-related non-Hodgkin lymphoma (NHL), correlating with loss of CD4+ T cells. The aim of the present study was to determine the role of EBV-specific CD4+ T cells in the development of NHL during chronic HIV infection. To this end, CD4+ and CD8+ memory T cells, capable of both proliferation and subsequent interferon gamma (IFNgamma) production, directed against a latent (Epstein-Barr virus nuclear antigen 1 [EBNA1]) and a lytic (BamH fragment Z left frame 1 [BZLF1]) EBV antigen were studied longitudinally in 9 progressors to NHL, 4 progressors to non-EBV-related AIDS, and 4 slow progressors to AIDS. In all 3 groups we observed a decline of EBV-specific memory CD4+ and CD8+ T-cell responses during HIV infection. However, whereas latent antigen EBNA1-specific CD4+ T cells were lost well before diagnosis in all subjects who developed an AIDS-related NHL (and EBNA1-specific CD8+ T cells were significantly lower compared with the other groups), these cells were better preserved in progressors to non-EBV-related disease and slow progressors. Loss of EBNA1-specific T-cell immunity thus might be important for progression to NHL. Interestingly, BZLF1-specific T cells were not lost in all progressors to NHL, suggesting a different function of these cells in the surveillance of EBV-infected B cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014568     DOI: 10.1182/blood-2005-01-0432

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

1.  Detailed analysis of Epstein-Barr virus-specific CD4+ and CD8+ T cell responses during infectious mononucleosis.

Authors:  J Scherrenburg; E R W A N Piriou; N M Nanlohy; D van Baarle
Journal:  Clin Exp Immunol       Date:  2008-06-28       Impact factor: 4.330

2.  Epstein-Barr virus-specific CD8(+) T lymphocytes from diffuse large B cell lymphoma patients are functionally impaired.

Authors:  D Cárdenas; G Vélez; A Orfao; M V Herrera; J Solano; M Olaya; A M Uribe; C Saavedra; M Duarte; M Rodríguez; M López; S Fiorentino; S Quijano
Journal:  Clin Exp Immunol       Date:  2015-09-11       Impact factor: 4.330

Review 3.  Diagnosis and management of lymphomas and other cancers in HIV-infected patients.

Authors:  Antonino Carbone; Emanuela Vaccher; Annunziata Gloghini; Liron Pantanowitz; Akin Abayomi; Paolo de Paoli; Silvia Franceschi
Journal:  Nat Rev Clin Oncol       Date:  2014-03-11       Impact factor: 66.675

4.  Pathogen-specific T cell depletion and reactivation of opportunistic pathogens in HIV infection.

Authors:  Christof Geldmacher; Richard A Koup
Journal:  Trends Immunol       Date:  2012-03-05       Impact factor: 16.687

Review 5.  Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.

Authors:  Nishitha Reddy; Katayoun Rezvani; A John Barrett; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-21       Impact factor: 5.742

6.  Adenovirus-based vaccines against rhesus lymphocryptovirus EBNA-1 induce expansion of specific CD8+ and CD4+ T cells in persistently infected rhesus macaques.

Authors:  R Leskowitz; M H Fogg; X Y Zhou; A Kaur; E L V Silveira; F Villinger; P M Lieberman; F Wang; H C Ertl
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

Review 7.  Immune escape by Epstein-Barr virus associated malignancies.

Authors:  Christian Münz; Ann Moormann
Journal:  Semin Cancer Biol       Date:  2008-10-19       Impact factor: 15.707

Review 8.  Cancer prevention in HIV-infected populations.

Authors:  Priscila H Goncalves; Jairo M Montezuma-Rusca; Robert Yarchoan; Thomas S Uldrick
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

9.  Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1.

Authors:  Kevin N Heller; Frida Arrey; Peter Steinherz; Carol Portlock; Amy Chadburn; Kara Kelly; Christian Münz
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

10.  Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses.

Authors:  Ann M Moormann; Kevin N Heller; Kiprotich Chelimo; Paula Embury; Robert Ploutz-Snyder; Juliana A Otieno; Margaret Oduor; Christian Münz; Rosemary Rochford
Journal:  Int J Cancer       Date:  2009-04-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.